Publications

Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V,… Suh M, Reichert H, Mezzi K, Fryzek J, et al. 2024. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur J Cancer 202:113975, doi: 10.1016/j.ejca.2024.113975.

Nelms MD, Antonijevic T, Ring C, Harris DL, Bever RJ, Lynn SG, … Borghoff S, et al. 2024. Chemistry domain of applicability evaluation against existing estrogen receptor high-throughput assay-based activity models. Front Toxicol 6:https://doi.org/10.3389/ftox.2024.1346767.

Mittal L, Perry C, Blanchette AD, Proctor DM. 2024. Probabilistic risk assessment of residential exposure to electric arc furnace steel slag using Bayesian model of relative bioavailability and PBPK modeling of manganese. Risk Analysis, open access.

Heintz MM, Klaren WD, East AW, Haws LC, McGreal SR, Campbell RR, Thompson CM. 2024. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes. Toxicol Sci kfae044. doi: 10.1093/toxsci/kfae044. Online ahead of print. PMID: 38574381

Heintz MM, Klaren WD, East AW, Haws LC, McGreal SR, Campbell RR, Thompson CM. 2024. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mouse hepatocytes. Toxicol Sci kfae045. doi: 10.1093/toxsci/kfae045. Online ahead of print. PMID: 38574385.

Bever RJ, Edwards SW, Antonijevic T, Nelms MD, Ring C, Harris D, Lynn SG, Williams D, Chappell G, Boyles R, Borghoff S, Markey KJ. 2024. Optimizing androgen receptor prioritization using high-throughput assay-based activity models. Front Toxicol 6:1347364; doi: 10.3389/ftox.2024.1347364.

Racz L, Gauthier A, Bare J, Heintz M, Feifarek D, Kennedy S, Panko J. 2024. Assessment of perfluorocarboxylic acids in fluorinated high-density polyethylene containers and estimation of potential non-cancer risks associated with anticipated use scenarios. Regul Toxicol Pharmacol 147:105560; doi: 10.1016/j.yrtph.2024.105560.

Fitch S, Blanchette A, Haws LC, Franke K, Ring C, DeVito M,… Wikoff DS. 2024. Systematic update to the mammalian relative potency estimate database and development of best estimate toxic equivalency factors for dioxin-like compounds. Regul Toxicol Pharmacol 147:105571; doi: 10.1016/j.yrtph.2024.105571.

DeVito M, Bokkers B, van Duursen MBM, van Ede K, Feeley M, Antunes Fernandes Gaspar E, Haws L,… Wikoff DD, et al. 2024. The 2022 World Health Organization reevaluation of human and mammalian toxic equivalency factors for polychlorinated dioxins, dibenzofurans and biphenyls. Regul Toxicol Pharmacol 146:105525; doi: 10.1016/j.yrtph.2023.105525

Ring C, Blanchette A, Klaren WD, Fitch S, Haws L, Wheeler MW, DeVito MJ, Walker N, Wikoff D. 2023. A multi-tiered hierarchical Bayesian approach to derive toxic equivalency factors for dioxin-like compounds. Regul Toxicol Pharmacol 143(11):105464; doi: 10.1016/j.yrtph.2023.105464.